M Odette Gore

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2076044/publications.pdf

Version: 2024-02-01

567281 501196 30 928 15 28 citations h-index g-index papers 32 32 32 1945 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Age- and Sex-Dependent Upper Reference Limits for the High-Sensitivity Cardiac Troponin T Assay. Journal of the American College of Cardiology, 2014, 63, 1441-1448.	2.8	303
2	Homoarginine and Cardiovascular Outcome in the Population-Based Dallas Heart Study. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 2501-2507.	2.4	73
3	Inaccuracy of Estimated Resting Oxygen Uptake in the Clinical Setting. Circulation, 2014, 129, 203-210.	1.6	69
4	Symmetrical Dimethylarginine Predicts Mortality in the General Population. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 2682-2688.	2.4	62
5	Racial Differences in Cardiovascular Biomarkers in the General Population. Journal of the American Heart Association, 2019, 8, e012729.	3.7	58
6	Diabetes Mellitus and Trends in Hospital Survival After Myocardial Infarction, 1994 to 2006. Circulation: Cardiovascular Quality and Outcomes, 2012, 5, 791-797.	2.2	45
7	The 10-year post-trial follow-up of the United Kingdom Prospective Diabetes Study (UKPDS): cardiovascular observations in context. Diabetes and Vascular Disease Research, 2009, 6, 53-55.	2.0	33
8	Association of prediabetes by fasting glucose and/or haemoglobin A1c levels with subclinical atherosclerosis and impaired renal function: Observations from the Dallas Heart Study. Diabetes and Vascular Disease Research, 2014, 11, 11-18.	2.0	33
9	Cardiovascular disease and type 2 diabetes mellitus: Regulating glucose and regulating drugs. Current Cardiology Reports, 2009, 11, 258-263.	2.9	29
10	Adiponectin and cardiovascular risk profile in patients with type 2 diabetes mellitus: parameters associated with adiponectin complex distribution. Diabetes and Vascular Disease Research, 2011, 8, 190-194.	2.0	24
11	Resolving drug effects from class effects among drugs for type 2 diabetes mellitus: more support for cardiovascular outcome assessments. European Heart Journal, 2011, 32, 1832-1834.	2.2	24
12	A Test in Context. Journal of the American College of Cardiology, 2016, 68, 2479-2486.	2.8	23
13	Identifying Familial Hypercholesterolemia Using a Blood Donor Screening Program With More Than 1 Million Volunteer Donors. JAMA Cardiology, 2019, 4, 685.	6.1	17
14	Renal phosphate wasting due to tumor-induced osteomalacia: a frequently delayed diagnosis. Kidney International, 2009, 76, 342-347.	5.2	16
15	The effects of rosiglitazone on myocardial triglyceride content in patients with type 2 diabetes: A randomised, placebo-controlled trial. Diabetes and Vascular Disease Research, 2012, 9, 131-137.	2.0	16
16	Accuracy of Estimating Resting Oxygen Uptake and Implications for Hemodynamic Assessment. American Journal of Cardiology, 2012, 109, 594-598.	1.6	15
17	Combining Biomarkers and Imaging for Shortâ€√erm Assessment of Cardiovascular Disease Risk in Apparently Healthy Adults. Journal of the American Heart Association, 2020, 9, e015410.	3.7	14
18	Elements of Social Convoy Theory in Mobile Health for Palliative Care: Scoping Review. JMIR MHealth and UHealth, 2020, 8, e16060.	3.7	14

#	Article	IF	CITATIONS
19	Discordant effects of rosiglitazone on novel inflammatory biomarkers. American Heart Journal, 2013, 165, 609-614.	2.7	10
20	Clinical Relevance of the 99th Percentile Upper Reference Limit for High-Sensitivity Cardiac Troponin Assays. Clinical Chemistry, 2020, 66, 403-405.	3.2	9
21	Insulin Resistance and Risk for Incident Heart Failure â^—. JACC: Heart Failure, 2013, 1, 537-539.	4.1	8
22	Assessment of cardiac structure and function in patients without and with peripheral oedema during rosiglitazone treatment. Diabetes and Vascular Disease Research, 2011, 8, 101-108.	2.0	7
23	High prevalence of elevated haemoglobin A1C among adolescent blood donors: Results from a voluntary screening programme including 31,546 adolescents. Diabetes and Vascular Disease Research, 2015, 12, 272-278.	2.0	6
24	Diabetes and Heart Failure in Patients With Coronary Disease: Separating Markers From Mediators. Diabetes Care, 2010, 33, 2120-2122.	8.6	5
25	ls cardiorespiratory fitness a determinant of cardiomyopathy in the setting of type 2 diabetes?. Diabetes and Vascular Disease Research, 2014, 11, 343-351.	2.0	5
26	Drugs for type 2 diabetes mellitus: The imperative for cardiovascular outcome assessment. Diabetes and Vascular Disease Research, 2012, 9, 85-88.	2.0	4
27	Effect of treatment with rosiglitazone on high-sensitivity cardiac troponin levels among patients with type 2 diabetes mellitus. Diabetes and Vascular Disease Research, 2016, 13, 113-118.	2.0	3
28	A Pilot Study and Ecological Model of Smoking Cues to Inform Mobile Health Strategies for Quitting Among Low-Income Smokers. Health Promotion Practice, 2021, 22, 850-862.	1.6	3
29	Cardiovascular Risk Factor Knowledge among Monolingual Hispanics. Journal of Health Care for the Poor and Underserved, 2021, 32, 688-699.	0.8	O
30	A Point-of-Care Algorithm to Guide Proper Device Selection for Ambulatory Electrocardiography. Critical Pathways in Cardiology, 2021, 20, 140-142.	0.5	0